Clinical Trial Search

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Response Rate — .125 proportion of participants

Primary: Overall Survival — 24.8 Months

Primary: Recurrence Free Survival — 15.6 months

Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Progression Free Survival With the Combination of GDC-0449 With Gemcitabine and Nab-paclitaxel. — 5.42 months

Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants

Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants

Primary: Progression-free Survival — 2 Participants

Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Complete Response Rate — 2; 15; 4; 3 Participants

Primary: Late Gastrointestinal Toxicities — 13 Participants

Primary: Overall Survival (OS) — 9.38; 14.7 Months

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Proportion of Evaluable Participants Who Experience Clinical Benefit (Disease Control Rate = Complete Response (CR)+Partial Response (PR)+Stable Disease x16 Weeks)…

Primary: Survival — 37; 31 participants